Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Inclusion Criteria:

* Aged at least 20 years
* Histological or cytological confirmation of a solid malignant tumour, excluding lymphoma, that is refractory to standard therapies or for which no standard therapies exist
* At least one lesion (measurable and/or non-measurable) that can be accurately assessed according to RECIST
* World Health Organisation (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks
* Patients should be willing to remain in hospital until the completion of the first cycle including cycle 0, cycle 1, and cycle 2 Day1 (as cycle 1 Day 21)

Exclusion Criteria:

* Clinically significant abnormalities of glucose metabolism as defined by any of the following:
* Diagnosis of diabetes mellitus type I or II (irrespective of management)
* Baseline fasting glucose value of ≥7 mmol/l (126mg/dL)
* Glycosylated haemoglobin (HbA1C) \>6.5%
* Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment
* Inadequate bone marrow reserve or organ function
* Any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection
* With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment